Eli Lilly and Incyte report atopic dermatitis data of baricitinib
Eli Lilly submitted a regulatory application of baricitinib in Europe for moderate to severe atopic dermatitis. Credit: Paul Sableman.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more